How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Lab Rat Market
- By Species: Rattus norvegicus (Norway rat), Rattus rattus (Black rat), Mus musculus (House mouse), Guinea pig (Cavia porcellus), Hamster (Mesocricetus auratus)
- By Genetic Modification Status: Wild-type, Knockout models, Transgenic models, Humanized models, Conditional mutants
- By Age Group: Neonatal, Juvenile, Adult, Aged
- By Health Status: Specific Pathogen Free (SPF), Germ-Free, Conventional, Immunodeficient
- By Purpose of Use: Toxicology testing, Pharmacology research, Behavioral studies, Oncology research, Genetic studies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Rattus norvegicus (Norway rat) leads By Species at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Lab Rat Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Species 5
Genetic Modification Status 5
Age Group 4
Health Status 4
Purpose of Use 5
Companies profiled
Biolasco Taiwan
Charles River
Envigo
Janvier Labs
Taconic Biosciences
Jackson Laboratory
JMSR
Joinn Laboratories
Pharmaron
GemPharmatech
Beijing Vital River Laboratory Animal Technology
Shanghai Model Organisms Center
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Biolasco Taiwan
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Charles River
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Envigo
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Janvier Labs
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Taconic Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Jackson Laboratory
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →JMSR
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Joinn Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Pharmaron
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →GemPharmatech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Beijing Vital River Laboratory Animal Technology
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Shanghai Model Organisms Center
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Beijing Biocytogen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,701M by 2033 · 3.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Rattus norvegicus (Norway rat)45.1
- Rattus rattus (Black rat)8.2
- Mus musculus (House mouse)19.2
- Guinea pig (Cavia porcellus)14.6
- Hamster (Mesocricetus auratus)12.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$429.7M → $624.1M · 4.8%
Europe$299.5M → $362.2M · 2.4%
Asia Pacific$273.4M → $322.3M · 2.1%
Latin America$169.3M → $214.5M · 3.0%
Middle East and Africa$130.2M → $171.2M · 3.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.342026
3.352027
3.372028
3.392029
3.392030
3.402031
3.422032
3.442033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Biolasco Taiwan18.8
- Charles River13.9
- Envigo10.1
- Janvier Labs8.5
- Taconic Biosciences13.2
- Jackson Laboratory7.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Species24.2%
Genetic Modification Status20.9%
Age Group12.0%
Health Status24.9%
Purpose of Use18.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.8
- Europe21.4
- Asia Pacific19.0
- Latin America12.7
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Biolasco Taiwan | 77 | 73 | 74 | 97 | 83 | 84 | 81 |
| Charles River | 76 | 73 | 69 | 87 | 88 | 74 | 78 |
| Envigo | 73 | 84 | 81 | 78 | 87 | 88 | 82 |
| Janvier Labs | 59 | 72 | 57 | 81 | 78 | 78 | 71 |
| Taconic Biosciences | 68 | 63 | 59 | 70 | 72 | 69 | 67 |
| Jackson Laboratory | 56 | 53 | 47 | 63 | 53 | 50 | 54 |
| JMSR | 46 | 43 | 40 | 50 | 48 | 52 | 47 |
| Joinn Laboratories | 35 | 46 | 38 | 40 | 37 | 56 | 42 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Biolasco Taiwan
- Charles River
- Envigo
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Biolasco Taiwan | ✓ | ◐ | − | ◐ | ✓ | ◐ |
| Charles River | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Envigo | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Janvier Labs | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Taconic Biosciences | − | ◐ | − | − | − | ◐ |
| Jackson Laboratory | − | − | − | ◐ | − | − |
| JMSR | ◐ | − | − | ◐ | − | ◐ |
| Joinn Laboratories | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Envigo82
2Biolasco Taiwan81
3Charles River78
4Janvier Labs71
5Taconic Biosciences67
6Jackson Laboratory54
7JMSR47
8Joinn Laboratories42
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Biolasco TaiwanCharles RiverEnvigo
Challenger2
Strong scale, closing on the leaders.
Janvier LabsTaconic Biosciences
Niche3
Specialists in a single segment or region.
Jackson LaboratoryJMSRJoinn Laboratories
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Species in North America, then scale across Lab Rat Market — a $402M beachhead inside a $6.13B market.
Beachhead (SOM)$402Mobtainable near-term
Serviceable (SAM)$2.15Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Rattus norvegicus (Norway rat)
Best fit — highest urgency & budget in Species.
Economic buyer78 fit
Rattus rattus (Black rat)
Strong fit — clear ROI and a fast path to value.
End user70 fit
Mus musculus (House mouse)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Species in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Genetic Modification Status & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Age Group
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel25%
Digital / self-serve21%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Species leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Lab Rat Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation15%
Closed-won6%
$12.4KCAC
$66KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Lab Rat Market is a high-growth opportunity — $2.92B by 2033, compounding at 11.5%.
TAM · 2025$1.22Btoday
TAM · 2033$2.92Bforecast
CAGR11.5%2027–2033
Cumulative$17.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.92BTotal addressable market
SAM$1.08BServiceable available market
SOM$182MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.5% CAGR
Demand compounds through 2033, outpacing GDP across Species.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Species moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.92BLarge & growingTAM by 2033 at 11.5% CAGR
$1.08BServiceable nowreachable with today’s model
$182MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.28BBear7.5% CAGR
$2.92BBase11.5% CAGR
$3.74BBull15.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Genetic Modification Status optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Lab Rat Market — a $7.01B market by 2033. Plan: grow share from 11.3% to 18.7%.
Market size · 2033$7.01Btotal addressable
Market CAGR6.9%2027–2033
Target share18.7%from 11.3% today
Revenue ambition$1.31Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.3% | 18.7% | At risk |
| Revenue | $762M | $1.31B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 32.2% | 41.9% | Ahead |
| Customer retention | 89.5% | 94.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Species
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Genetic Modification Status capability
A defensible second engine — invest in Genetic Modification Status to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Species share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Genetic Modification Status
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $169M capacity & capability investment
- Greenlight bolt-on M&A in Genetic Modification Status
- Authorise North America expansion plan
- Fund R&D program for Species leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Lab Rat Market conversation — a $7.47B market you can size, segment and defend in minutes.
Market size · 2033$7.47Btotal opportunity
Growth11.3%CAGR to 2033
Addressable buyers1,662+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Species
Goal Grow share in Species
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 2 mopayback period
$61K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Biolasco TaiwanCharles RiverEnvigoJanvier LabsTaconic BiosciencesJackson LaboratoryJMSRJoinn Laboratories+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Lab Rat Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Lab Rat Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Labour Delivery Room Bed (LDR) Beds Market
Labour Delivery Room Bed (LDR) Beds Market is valued at USD 720 Million in 2025 and is expected…
$720M market · 2025 base year
View reportLabor Protection Articles Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportLabor Pain Drug Market
Market size, share, segmentation and regional forecast.
$776M market · 2025 base year
View reportLabor Insurance Supplies Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportLaboratory Weighing Scale Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportLaboratory Washer Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportLaboratory Ware Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportLaboratory Vortex Mixing System Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportLaboratory Vial Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportLaboratory Vertical Freezer Market
Market size, share, segmentation and regional forecast.
$841M market · 2025 base year
View reportLaboratory Vertical Autoclave Market
Market size, share, segmentation and regional forecast.
$598M market · 2025 base year
View reportLaboratory Vacuum Drying Oven Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.